Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_1
1
20%
Ph early_phase_1
1
20%
Ph phase_3
3
60%

Phase Distribution

2

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
1(20.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Other(1)

Detailed Status

Completed4
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (20.0%)
Phase 11 (20.0%)
Phase 33 (60.0%)

Trials by Status

completed480%
unknown120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects

NCT01733186
completedphase_3

Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus

NCT04310215
completedphase_3

Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury

NCT01041001
completedphase_3

Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect

NCT01626677
unknownearly_phase_1

Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product

NCT02338375

Clinical Trials (5)

Showing 5 of 5 trials
NCT01733186Phase 1

Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects

Completed
NCT04310215Phase 3

Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus

Completed
NCT01041001Phase 3

Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury

Completed
NCT01626677Phase 3

Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect

Completed
NCT02338375Early Phase 1

Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product

Unknown

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5